Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has undergone rapid changes with innovations in oncogene-directed therapy and immune checkpoint inhibitors. In patients with epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC, newer-generation tyrosine...
Saved in:
Main Authors: | Nathaniel Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/8a8afaf9374b4c2f8f1ca6eb45e8a49c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
by: Tian Tian, et al.
Published: (2021) -
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
by: Yang W, et al.
Published: (2020) -
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
by: Yi-Dan Yan, et al.
Published: (2021) -
Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
by: Syahruddin E, et al.
Published: (2018) -
Oligoprogression in Non-Small Cell Lung Cancer
by: Daijiro Harada, et al.
Published: (2021)